Related Experiment Video
Updated: Jul 11, 2026

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
Limitations of current prophylaxis against influenza virus infection
Mario Guralnik1, Richard A Rosenbloom, Michael P Petteruti
1Synergy Research, Teaneck, NJ; and 2Quigley Pharma, Doylestown, PA, USA. Mario.guralnik@synergy-cro.com
Abstract:
Avian influenza has been a source of worldwide concern since Hong Kong authorities detected the first outbreak in 1997. Mainly as a result of poultry-to-human transmission, more than 200 cases of infection in humans have been attributed to the A/H5, A/H7, and A/H9 viral subtypes, with a case fatality rate for A/H5N1 infections exceeding 50%. A mutant or reassortant virus capable of efficient human-to-human transmission can set off a pandemic. Increased attention to prophylaxis against viral infection has identified several potentially complementary approaches: nonpharmacologic measures (eg, travel restrictions), vaccination, chemotherapeutic agents, and herbal/natural products. All have significant limitations that point out the need for additional modalities. Herbal/natural products, particularly those based on green tea extract, offer promise as adjuncts or alternatives to current interventions and warrant further evaluation in well-controlled human trials.
More Related Videos
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
04:47A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
Published on: February 23, 2018
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Vaccinations
Influenza
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Respiratory Syncytial Virus Disease